companiesCompany
Hansoh Pharmaceutical
Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.
Overview
Hansoh developed aumolertinib, a third-generation EGFR TKI approved by the NMPA in 2020 and by the EU in 2026 for EGFR-mutant NSCLC, and has out-licensed ADC and GLP-1 assets to GSK and Merck & Co.
Headquarters
Lianyungang, Jiangsu, CN
Scorecard
All companies#96of 680 companies, score 27
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +15
1 approved, 0 in phase 3, 0 earlier, 1 targets, 59 registry studies. Formula on the scorecards page.
Type
pharma · 3692.HK
Stage
Public
Website